COMMUNIQUÉS West-GlobeNewswire

Incyclix Bio Appoints Dr. Andrew Beelen as Vice President of Clinical Development
20/08/2024
RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of [...]
LAVA Reports Second Quarter 2024 Financial Results and Business Update
20/08/2024
Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combination Favorable safety profile for LAVA-1207 Next data update [...]
The Joint Corp. to Participate in the 7th Annual B. Riley Securities Consumer & TMT Conference
20/08/2024
SCOTTSDALE, Ariz., Aug. 20, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network , announced that management plans to [...]
Infectious Disease Expert Kelly Warfield Named Sabin’s New R&D President
20/08/2024
caption: Sabin Vaccine Institute Research & Development President Kelly Warfield WASHINGTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Virologist and vaccine development leader Kelly Warfield has joined the Sabin Vaccine [...]
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication
20/08/2024
CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department More than 27,569 individuals in the U.S. died from drug overdose deaths involving cocaine [...]
Algernon Pharmaceuticals Announces Closing of Private Placement
20/08/2024
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: [...]
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/08/2024
REDWOOD CITY, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
19/08/2024
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS- [...]
Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.
19/08/2024
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) [...]
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
19/08/2024
The clinical trial for SCI-210 is conducted in Israel, after which the Company aims to move forward with the commercialization process of SCI-210, first in the Israeli market TEL AVIV, Israel, Aug. 19, 2024 (GLOBE [...]
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
19/08/2024
IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment [...]
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
19/08/2024
BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
19/08/2024
BOTHELL, Wash., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) management announces its participation in the upcoming Virtual Investor Summit Microcap Forum in August and the H.C. Wainwright [...]
Kymera Therapeutics Announces Proposed Public Offering
19/08/2024
WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein [...]
Stryker to participate in the 2024 Wells Fargo Healthcare Conference
19/08/2024
Portage, Michigan, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, at the Encore Boston Harbor. Spencer Stiles, Group [...]
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
19/08/2024
Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse [...]
Scorpius Holdings, Inc. Announces Closing of Public Offering
19/08/2024
DURHAM, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced [...]
Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment
19/08/2024
Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment  Experienced executive to lead preparations for U.S. [...]
Tony Tipton nommé au poste de directeur des opérations États-Unis de Crossject en vue de la commercialisation de ZEPIZURE®, traitement d'urgence dans la prise en charge des crises d’épilepsie
19/08/2024
Communiqué de presse Tony Tipton nommé au poste de directeur des opérations États-Unis de Crossject en vue de la commercialisation de ZEPIZURE®, traitement d'urgence dans la prise en charge des crises d’épilepsie  Ce [...]

Pages